
Pier Woudstra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5205837/publications.pdf Version: 2024-02-01



DIED WOUDSTDA

#	Article	IF	CITATIONS
1	Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: AÂpathology study. Atherosclerosis, 2015, 241, 772-782.	0.4	151
2	P2Y12 platelet inhibition in clinical practice. Journal of Thrombosis and Thrombolysis, 2012, 33, 143-153.	1.0	97
3	1-Year Outcome of TRIAS HR (TRI-Stent Adjudication Study–High Risk of Restenosis). JACC: Cardiovascular Interventions, 2011, 4, 896-904.	1.1	49
4	1-Year Results of the REMEDEEÂRegistry. JACC: Cardiovascular Interventions, 2016, 9, 1127-1134.	1.1	45
5	Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure. Journal of Cardiovascular Medicine, 2013, 14, 438-445.	0.6	32
6	Early Invasive Versus Selective Strategy forÂNon–ST-Segment Elevation AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2017, 69, 1883-1893.	1.2	29
7	Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies. EuroIntervention, 2013, 9, 195-203.	1.4	27
8	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. JACC: Cardiovascular Interventions, 2018, 11, 1969-1978.	1.1	21
9	One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent. International Journal of Cardiology, 2017, 226, 60-64.	0.8	20
10	Next-generation DES: the COMBO dual therapy stent with Genous endothelial progenitor capturing technology and an abluminal sirolimus matrix. Expert Review of Medical Devices, 2014, 11, 121-135.	1.4	17
11	Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis. Annals of Epidemiology, 2013, 23, 415-421.	0.9	16
12	Clinical outcomes after final kissing balloon inflation compared with no final kissing balloon inflation in bifurcation lesions treated with a dedicated coronary bifurcation stent. Heart, 2014, 100, 479-486.	1.2	14
13	Evaluation of clinical outcomes after C <scp>OMBO</scp> stent treatment in patients presenting with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2017, 90, E31-E37.	0.7	13
14	Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. Open Heart, 2017, 4, e000634.	0.9	13
15	Coronary Stenting With the GenousTM Bio-Engineered R StentTM in Elderly Patients - 12-Month Outcomes From the e-HEALING Registry Circulation Journal, 2011, 75, 2590-2597.	0.7	11
16	Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis. EuroIntervention, 2017, 13, 1202-1209.	1.4	11
17	Three-Year Clinical Follow-Up of an Unselected Patient Population Treated with the Genous Endothelial Progenitor Cell Capturing Stent. Journal of Interventional Cardiology, 2011, 24, 442-449.	0.5	10
18	1-Year Clinical Outcomes of AllÂComersÂTreated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 820-830.	1.1	10

PIER WOUDSTRA

#	Article	IF	CITATIONS
19	Short―and Longâ€Term Prognostic Value of the TIMI Risk Score after Primary Percutaneous Coronary Intervention for STâ€segment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 8-13.	0.5	9
20	Prognostic relevance of PCI-related myocardial infarction. Nature Reviews Cardiology, 2013, 10, 231-236.	6.1	9
21	Five-year clinical follow-up of the STENTYS self-apposing stent in complex coronary anatomy: aÂsingle-centre experience with report of specific angiographic indications. Netherlands Heart Journal, 2018, 26, 263-271.	0.3	9
22	Threeâ€year clinical outcomes after dualâ€therapy COMBO stent placement: Insights from the REMEDEE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 342-347.	0.7	8
23	Twelve-month clinical outcomes after coronary stenting with the Genous Bio-engineered R Stent in patients with a bifurcation lesion. Coronary Artery Disease, 2012, 23, 201-207.	0.3	7
24	Percutaneous coronary intervention for acute coronary syndrome due to graft failure. Catheterization and Cardiovascular Interventions, 2014, 83, 203-209.	0.7	7
25	Side branch healing patterns of the Tryton dedicated bifurcation stent: a 1-year optical coherence tomography follow-up study. International Journal of Cardiovascular Imaging, 2014, 30, 1445-1456.	0.7	7
26	Gender difference in the prognostic value of estimated glomerular filtration rate at admission in ST-segment elevation myocardial infarction: a prospective cohort study. BMJ Open, 2012, 2, e000322.	0.8	6
27	Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. American Heart lournal, 2012, 163, 783-789.	1.2	6
28	Final fiveâ€year results of the REMEDEE Registry: Realâ€world experience with the dualâ€ŧherapy COMBO stent. Catheterization and Cardiovascular Interventions, 2020, 98, 503-510.	0.7	6
29	Fiveâ€year followâ€up of the endothelial progenitor cell capturing stent versus the paxlitaxelâ€eluting stent in de novo coronary lesions with a high risk of coronary restenosis. Catheterization and Cardiovascular Interventions, 2018, 91, 1212-1218.	0.7	4
30	Sex differences in 1â€year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2021, 97, 797-804.	0.7	4
31	First-in-man intracoronary use of the Trevo® Pro 4 mechanical thrombectomy device for the retrieval of large intracoronary thrombus in patients with acute coronary syndromes. EuroIntervention, 2013, 9, 505-509.	1.4	4
32	Multiple biomarkers for the prediction of short and long-term mortality after ST-segment elevation myocardial infarction: the Amsterdam Groningen collaboration. Journal of Thrombosis and Thrombolysis, 2013, 36, 42-46.	1.0	3
33	Clinical outcomes after bareâ€metal stenting in diabetic patients with lesions carrying a low risk of restenosis. Catheterization and Cardiovascular Interventions, 2013, 81, 26-33.	0.7	3
34	Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent. Cardiovascular Revascularization Medicine, 2018, 19, 373-375.	0.3	3
35	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. Cardiovascular Revascularization Medicine, 2020, 21, 567-570.	0.3	3
36	Survival of Patients after ST-Elevation Myocardial Infarction: External Validation of a Predictive Biomarker Model. Clinical Chemistry, 2012, 58, 1063-1064.	1.5	2

#	Article	lF	CITATIONS
37	Dutch cardiology residents and the COVID-19 pandemic: Every little thing counts in aÂcrisis. Netherlands Heart Journal, 2020, 28, 625-627.	0.3	2
38	Admission Lipoprotein-Associated Phospholipase A2 Activity Is Not Associated with Long-Term Clinical Outcomes after ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2014, 9, e96251.	1.1	2
39	Ten-year outcomes of an early invasive or a selective invasive strategy in non-ST-segment elevation acute coronary syndrome patients with and without diabetes mellitus: a subgroup analysis of the ICTUS trial. Coronary Artery Disease, 2020, 31, 95-97.	0.3	1
40	A multiple biomarker risk score predicts long-term mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. European Heart Journal, 2013, 34, P1273-P1273.	1.0	0